<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117792">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569568</url>
  </required_header>
  <id_info>
    <org_study_id>UCRDC 5107</org_study_id>
    <nct_id>NCT01569568</nct_id>
  </id_info>
  <brief_title>Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI</brief_title>
  <official_title>Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrea Gropman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use various types of MRI and cognitive testing to evaluate
      changes in the brain and cognitive function that occur in subjects with ornithine
      transcarbamylase deficiency (OTCD) relative to healthy individuals
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of this project is to characterize metabolic, structural and cognitive
      changes in OTCD using 1H MRS, DTI, volumetric averaging and fMRI with cognitive testing of
      executive function measures to validate biomarkers for the effect of HA and its treatment on
      the brain.

      We will measure gln and mI in blood and brain (using 1H MRS) in affected participants, and
      mI in brain in controls, fractional anisotropy as a measure of white matter microstructural
      damage (by DTI) and brain activation pathways alterations with tasks probing working memory
      (fMRI). As a secondary outcome measure, we will correlate the findings from neuroimaging
      with cognitive functioning. This protocol is based on our previous 5104 and now includes
      children to evaluate the age and stage of disease on these indices in a cohort that is
      undergoing important developmental events against an age matched typically developing
      cohort.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough enrollment
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker characterization</measure>
    <time_frame>Baseline</time_frame>
    <description>To characterize metabolic, structural and cognitive changes in OTCD by 1H MRS, DTI, volumetric measures, and fMRI and to validate biomarkers for the effect of HA and its treatment on the brain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of imaging markers with cognitive function</measure>
    <time_frame>Baseline</time_frame>
    <description>To correlate the findings from neuroimaging with cognitive functioning and clinical parameters.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">68</enrollment>
  <condition>Ornithine Transcarbamylase Deficiency</condition>
  <arm_group>
    <arm_group_label>Subjects with OTCD</arm_group_label>
    <description>males and females ages 7-60 years with OTCD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>males and females ages 7-60 years who are healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MRI scanning</intervention_name>
    <description>1H MRS, DTI, FMRI</description>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive testing</intervention_name>
    <description>Neuropsychological testing</description>
    <arm_group_label>Subjects with OTCD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males and females, ages 7-60 years with ornithine transcarbamylase deficiency Males and
        females, ages 7-60 years who are healthy controls without ornithine transcarbamylase
        deficiency
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject inclusion criteria:

          1. Patients with OTCD;

          2. Age range: 7-60 years

          3. Able to undergo neuroimaging safely (i.e. without presence of ferromagnetic devices)

          4. Subject has a documented full scale IQ &gt; 70

        Control participant inclusion criteria:

          1. Healthy males and females without metabolic disease aged 7-60 years

          2. Subject has a documented full scale IQ &gt; 70

        Exclusion Criteria:

        Subject exclusion criteria:

          1. Mental retardation (i.e., Full Scale IQ&lt; 70)

          2. Age range &lt;7 or &gt;60 years

          3. Presence of ferromagnetic device(s) that preclude safe imaging

          4. Pregnant female

        Control exclusion criteria:

          1. Subjects with a documented history of an intellectual deficit (i.e., Full Scale IQ&lt;
             70)

          2. Age range &lt;7 or &gt;60 years

          3. Presence of ferromagnetic device(s) that preclude safe imaging

          4. Pregnant female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea L Gropman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://NUCDF.org</url>
    <description>Family support group</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/ucdc/</url>
    <description>Urea cycle consortium site</description>
  </link>
  <reference>
    <citation>Gropman AL, Shattuck K, Prust MJ, Seltzer RR, Breeden AL, Hailu A, Rigas A, Hussain R, VanMeter J. Altered neural activation in ornithine transcarbamylase deficiency during executive cognition: an fMRI study. Hum Brain Mapp. 2013 Apr;34(4):753-61. doi: 10.1002/hbm.21470. Epub 2011 Nov 23.</citation>
    <PMID>22110002</PMID>
  </reference>
  <reference>
    <citation>Prust MJ, Gropman AL, Hauser N. New frontiers in neuroimaging applications to inborn errors of metabolism. Mol Genet Metab. 2011 Nov;104(3):195-205. doi: 10.1016/j.ymgme.2011.06.020. Epub 2011 Jun 30. Review.</citation>
    <PMID>21778100</PMID>
  </reference>
  <reference>
    <citation>Gropman AL, Gertz B, Shattuck K, Kahn IL, Seltzer R, Krivitsky L, Van Meter J. Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine transcarbamylase deficiency. AJNR Am J Neuroradiol. 2010 Oct;31(9):1719-23. doi: 10.3174/ajnr.A2122. Epub 2010 May 20.</citation>
    <PMID>20488904</PMID>
  </reference>
  <reference>
    <citation>Gropman A. Brain imaging in urea cycle disorders. Mol Genet Metab. 2010;100 Suppl 1:S20-30. doi: 10.1016/j.ymgme.2010.01.017. Epub 2010 Feb 13. Review.</citation>
    <PMID>20207564</PMID>
  </reference>
  <reference>
    <citation>Oldham MS, VanMeter JW, Shattuck KF, Cederbaum SD, Gropman AL. Diffusion tensor imaging in arginase deficiency reveals damage to corticospinal tracts. Pediatr Neurol. 2010 Jan;42(1):49-52. doi: 10.1016/j.pediatrneurol.2009.07.017.</citation>
    <PMID>20004862</PMID>
  </reference>
  <reference>
    <citation>Gropman AL, Sailasuta N, Harris KC, Abulseoud O, Ross BD. Ornithine transcarbamylase deficiency with persistent abnormality in cerebral glutamate metabolism in adults. Radiology. 2009 Sep;252(3):833-41. doi: 10.1148/radiol.2523081878. Epub 2009 Jun 30.</citation>
    <PMID>19567648</PMID>
  </reference>
  <reference>
    <citation>Gropman AL, Fricke ST, Seltzer RR, Hailu A, Adeyemo A, Sawyer A, van Meter J, Gaillard WD, McCarter R, Tuchman M, Batshaw M; Urea Cycle Disorders Consortium.. 1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency. Mol Genet Metab. 2008 Sep-Oct;95(1-2):21-30. doi: 10.1016/j.ymgme.2008.06.003. Epub 2008 Jul 26.</citation>
    <PMID>18662894</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 22, 2014</lastchanged_date>
  <firstreceived_date>March 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Research Institute</investigator_affiliation>
    <investigator_full_name>Andrea Gropman</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Neuroimaging</keyword>
  <keyword>MRI</keyword>
  <keyword>Urea cycle</keyword>
  <keyword>hyperammonemia</keyword>
  <keyword>cognitive function</keyword>
  <keyword>ornithine transcarbamylase deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
